Hollow mesoporous silica nanoparticles for co-delivery of hydrophobic and hydrophilic molecules: mechanism of drug loading and release
Source abstract
Abstract
The objective of this study was to investigate the loading capacity and release profiles of curcumin (CUR), as a hydrophobic drug molecule, and doxorubicin hydrochloride (DOX), as a hydrophilic drug molecule, into hollow mesoporous silica nanoparticles (HMSNs) through a co-delivery system. The drug loading and release studies were conducted and analyzed by HPLC–UV. The hydrodynamic size and zeta potential of HMSNs were 206.8 nm and − 28.8 mV respectively. Drug loadings of DOX into HMSN-DOX NPs and HMSN-DOX-CUR NPs were 37.51 ± 2.07% and 18.57 ± 6.22% respectively, and the loading capacities of CUR in HMSN-CUR NPs and HMSN-DOX-CUR NPs were 61.57 ± 2.82% and 43.73 ± 8.3% respectively. The release study of DOX in phosphate buffer saline (PBS, pH = 7.4) showed that 10.36 ± 0.7% and 13.06 ± 0.26% of loaded DOX in HMSN-DOX NPs and HMSN-DOX-CUR NPs were released after 24 h, respectively, whereas 92.04 ± 3.89% and 95.53 ± 0.29% of the loaded CUR in HMSN-CUR NPs and HMSN-DOX-CUR NPs were released after 6 h in albumin 3%, pH = 7.4, respectively. The result of this study suggests that HMSNs can be used as a suitable candidate system for the delivery of hydrophilic drugs in cancer therapies, thanks to their ability to prevent premature drug release from NPs. On the other hand, the release study of CUR as a hydrophobic drug model suggests that the considered NPs may not be a suitable candidate for the delivery of such drugs in cancer therapies due to the rapid release of compounds in a simulated plasma model.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Mesoporous Materials and Catalysis · Curcumin's Biomedical Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (36)
Show source-provided references
1. Abdelaal HM, Shaikjee A (2020) Microwave-based fast synthesis of clear-cut hollow spheres with mesoporous wall of silica nanoparticles as excellent drug delivery vehicles. J Nanoparticle Res 22:1–9. https://doi.org/10.1007/s11051-020-04918-310.1007/s11051-020-04918-3 ↗
2. Abouelmagd SA, Sun B, Chang AC, Ku YJ, Yeo Y (2015) Release kinetics study of poorly water-soluble drugs from nanoparticles: are we doing it right? Mol Pharm 12:997–1003. https://doi.org/10.1021/mp500817h10.1021/mp500817h ↗
3. Akhter MH, Rizwanullah M, Ahmad J, Ahsan MJ, Mujtaba MA, Amin S (2018) Nanocarriers in advanced drug targeting: setting novel paradigm in cancer therapeutics. Artif Cells Nanomed Biotechnol 46:873–884. https://doi.org/10.1080/21691401.2017.136633310.1080/21691401.2017.1366333 ↗
4. Alrushaid S, Sayre CL, Yáñez JA, Forrest ML, Senadheera SN, Burczynski FJ, Löbenberg R, Davies NM (2017) Pharmacokinetic and toxicodynamic characterization of a novel doxorubicin derivative. Pharmaceutics 9.https://doi.org/10.3390/pharmaceutics903003510.3390/pharmaceutics9030035 ↗
5. Amann LC, Gandal MJ, Lin R, Liang Y, Siegel SJ (2010) In vitro-in vivo correlations of scalable PLGA-risperidone implants for the treatment of schizophrenia. Pharm Res 27:1730–1737. https://doi.org/10.1007/s11095-010-0152-410.1007/s11095-010-0152-4 ↗
6. Bharti C, Gulati N, Nagaich U, Pal A (2015) Mesoporous silica nanoparticles in target drug delivery system: a review. Int J Pharm Investig 5:124–133. https://doi.org/10.4103/2230-973x.16084410.4103/2230-973x.160844 ↗
7. Buch P, Holm P, Thomassen JQ, Scherer D, Branscheid R, Kolb U, Langguth P (2010) IVIVC for fenofibrate immediate release tablets using solubility and permeability as in vitro predictors for pharmacokinetics. J Pharm Sci 99:4427–4436. https://doi.org/10.1002/jps.2214810.1002/jps.22148 ↗
8. Chen F, Hong H, Shi S, Goel S, Valdovinos HF, Hernandez R, Theuer CP, Barnhart TE, Cai W (2014) Engineering of hollow mesoporous silica nanoparticles for remarkably enhanced tumor active targeting efficacy. Sci Rep 4.https://doi.org/10.1038/srep0508010.1038/srep05080 ↗
9. Chen Y, Gao Y, Chen H, Zeng D, Li Y, Zheng Y, Li F, Ji X, Wang X, Chen F, He Q, Zhang L, Shi J (2012) Engineering inorganic nanoemulsions/nanoliposomes by fluoride-silica chemistry for efficient delivery/co-delivery of hydrophobic agents. Adv Funct Mater 22:1586–1597. https://doi.org/10.1002/adfm.20110205210.1002/adfm.201102052 ↗
10. Croissant JG, Fatieiev Y, Khashab NM (2017) Degradability and clearance of silicon, organosilica, silsesquioxane, silica mixed oxide, and mesoporous silica nanoparticles. Adv Mater 29:1604634. https://doi.org/10.1002/ADMA.20160463410.1002/ADMA.201604634 ↗
11. Danhier F, Fabienne O, Préat V (2010) To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 148:135–146. https://doi.org/10.1016/J.JCONREL.2010.08.02710.1016/J.JCONREL.2010.08.027 ↗
12. Deepika D, PonnanEttiyappan JB (2018) Synthesis and characterization of microporous hollow core-shell silica nanoparticles (HCSNs) of tunable thickness for controlled release of doxorubicin. J Nanoparticle Res 20:1–15. https://doi.org/10.1007/s11051-018-4287-210.1007/s11051-018-4287-2 ↗
13. D’Souza S (2014) A review of in vitro drug release test methods for nano-sized dosage forms. Adv Pharm 2014:1–12. https://doi.org/10.1155/2014/30475710.1155/2014/304757 ↗
14. Fang J, Nakamura H, Maeda H (2011) The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 63:136–151. https://doi.org/10.1016/J.ADDR.2010.04.00910.1016/J.ADDR.2010.04.009 ↗
15. He Y, Shao L, Usman I, Hu Y, Pan A, Liang S, Xu H (2020) A pH-responsive dissociable mesoporous silica-based nanoplatform enabling efficient dual-drug co-delivery and rapid clearance for cancer therapy. Biomater Sci 8:3418–3429. https://doi.org/10.1039/d0bm00204f10.1039/d0bm00204f ↗
16. Hillerström A, Andersson M, Samuelsson J, Van Stam J (2014) Solvent strategies for loading and release in mesoporous silica. Colloids Interface Sci Commun 3:5–8. https://doi.org/10.1016/j.colcom.2015.01.00110.1016/j.colcom.2015.01.001 ↗
17. Huang YW, Wu CH, Aronstam RS (2010) Toxicity of transition metal oxide nanoparticles: recent insights from in vitro studies. Materials (Basel) 3:4842–4859. https://doi.org/10.3390/ma310484210.3390/ma3104842 ↗
18. Karavasili C, Andreadis DA, Katsamenis OL, Panteris E, Anastasiadou P, Kakazanis Z, Zoumpourlis V, Markopoulou CK, Koutsopoulos S, Vizirianakis IS, Fatouros DG (2019) Synergistic antitumor potency of a self-assembling peptide hydrogel for the local co-delivery of doxorubicin and curcumin in the treatment of head and neck cancer. Mol Pharm 16:2326–2341. https://doi.org/10.1021/acs.molpharmaceut.8b0122110.1021/acs.molpharmaceut.8b01221 ↗
19. Li S, Jiao X, Yang H (2013) Hydrophobic core/hydrophilic shell structured mesoporous silica nanospheres: enhanced adsorption of organic compounds from water. Langmuir 29:1228–1237. https://doi.org/10.1021/la303733w10.1021/la303733w ↗
20. Liu JL, Liu T, Pan J, Liu S, Max Lu GQ (2018) Advances in multicompartment mesoporous silica micro/nanoparticles or theranostic applications. Annu Rev Chem Biomol Eng 9:389–41110.1146/annurev-chembioeng-060817-084225 ↗
21. Maghsoudnia N, Eftekhari RB, Sohi AN, Zamzami A, Dorkoosh FA (2020) Application of nano-based systems for drug delivery and targeting: a review. J Nanoparticle Res 22:1–41. https://doi.org/10.1007/s11051-020-04959-810.1007/s11051-020-04959-8 ↗
22. Mistiran AF, Dzarr AA, Gan SH (2010) HPLC method development and validation for simultaneous detection of arabinoside-C and doxorubicin. Toxicol Mech Methods 20:472–481. https://doi.org/10.3109/15376516.2010.50324610.3109/15376516.2010.503246 ↗
23. Narayan R, Nayak UY, Raichur AM, Garg S (2018) Mesoporous silica nanoparticles: a comprehensive review on synthesis and recent advances. Pharmaceutics 10.https://doi.org/10.3390/pharmaceutics1003011810.3390/pharmaceutics10030118 ↗
24. Nelson KM, Dahlin JL, Bisson J, Graham J, Pauli GF, Walters MA (2017) The essential medicinal chemistry of curcumin. J Med Chem 60:1620–1637. https://doi.org/10.1021/acs.jmedchem.6b0097510.1021/acs.jmedchem.6b00975 ↗
25. Phillips DJ, Pygall SR, Cooper VB, Mann JC (2012) Overcoming sink limitations in dissolution testing: a review of traditional methods and the potential utility of biphasic systems. J Pharm Pharmacol 64:1549–1559. https://doi.org/10.1111/j.2042-7158.2012.01523.x10.1111/j.2042-7158.2012.01523.x ↗
26. Rahman SMH, Telny TC, Ravi TK, Kuppusamy S (2009) Role of surfactant and pH in dissolution of curcumin. Indian J Pharm Sci 71:139–142. https://doi.org/10.4103/0250-474X.5428010.4103/0250-474X.54280 ↗
27. Reddy KL, Sharma PK, Singh A, Kumar A, Shankar KR, Singh Y, Garg N, Krishnan V (2019) Amine-functionalized, porous silica-coated NaYF 4:Yb/Er upconversion nanophosphors for efficient delivery of doxorubicin and curcumin. Mater Sci Eng C 96:86–95. https://doi.org/10.1016/j.msec.2018.11.00710.1016/j.msec.2018.11.007 ↗
28. Souza SD’, Faraj JA, Giovagnoli S, Deluca PP (2014) IVIVC from long acting olanzapine microspheres. Int J Biomater 2014.https://doi.org/10.1155/2014/40706510.1155/2014/407065 ↗
29. Sun X, Luo Y, Huang L, Yu BY, Tian J (2017) A peptide-decorated and curcumin-loaded mesoporous silica nanomedicine for effectively overcoming multidrug resistance in cancer cells. RSC Adv 7:16401–16409. https://doi.org/10.1039/c7ra01128h10.1039/c7ra01128h ↗
30. Vallet-Regí M, Colilla M, Izquierdo-Barba I, Manzano M (2018) Mesoporous silica nanoparticles for drug delivery: current insights. Molecules 23.https://doi.org/10.3390/molecules2301004710.3390/molecules23010047 ↗
31. Yen F-L, Wu T-H, Tzeng C-W, Lin L-T, Lin C-C (2010) Curcumin nanoparticles improve the physicochemical properties of curcumin and effectively enhance its antioxidant and antihepatoma activities. J Agric Food Chem 58:7376–7382. https://doi.org/10.1021/jf100135h10.1021/jf100135h ↗
32. Zhai W, He C, Wu L, Zhou Y, Chen H, Chang J, Zhang H (2012) Degradation of hollow mesoporous silica nanoparticles in human umbilical vein endothelial cells. J Biomed Mater Res B Appl Biomater 100:1397–1403. https://doi.org/10.1002/JBM.B.3271110.1002/JBM.B.32711 ↗
33. Zhang Y, Hou Z, Ge Y, Deng K, Liu B, Li X, Li Q, Cheng Z, Ma P, Li C, Lin J (2015) DNA-hybrid-gated photothermal mesoporous silica nanoparticles for NIR-responsive and aptamer-targeted drug delivery. ACS Appl Mater Interfaces 7:20696–20706. https://doi.org/10.1021/acsami.5b0552210.1021/acsami.5b05522 ↗
34. Zhang Y, Yang C, Wang W, Liu J, Liu Q, Huang F, Chu L, Gao H, Li C, Kong D, Liu Q, Liu J (2016) Co-delivery of doxorubicin and curcumin by pH-sensitive prodrug nanoparticle for combination therapy of cancer. Sci Rep 6:1–12. https://doi.org/10.1038/srep2122510.1038/srep21225 ↗
35. Zhao X, Chen Q, Liu W, Li Y, Tang H, Liu X, Yang X (2014) Codelivery of doxorubicin and curcumin with lipid nanoparticles results in improved efficacy of chemotherapy in liver cancer. Int J Nanomed 10:257–270. https://doi.org/10.2147/IJN.S7332210.2147/IJN.S73322 ↗
36. Zhou Y, Quan G, Wu Q, Zhang X, Niu B, Wu B, Huang Y, Pan X, Wu C (2018) Mesoporous silica nanoparticles for drug and gene delivery. Acta Pharm Sin B 8:165–177. https://doi.org/10.1016/j.apsb.2018.01.00710.1016/j.apsb.2018.01.007 ↗